Comparing ADMA Biologics (ADMA) & Its Peers

ADMA Biologics (NASDAQ:ADMA – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare ADMA Biologics to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ADMA Biologics and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics 0 3 3 0 2.50
ADMA Biologics Competitors 9926 15343 45765 1601 2.54

ADMA Biologics presently has a consensus price target of $17.50, indicating a potential upside of 32.88%. As a group, “Biotechnology” companies have a potential upside of 114.76%. Given ADMA Biologics’ peers stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics has less favorable growth aspects than its peers.

Risk and Volatility

ADMA Biologics has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, ADMA Biologics’ peers have a beta of -1.85, meaning that their average share price is 285% less volatile than the S&P 500.

Earnings and Valuation

This table compares ADMA Biologics and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ADMA Biologics $510.17 million $146.93 million 17.10
ADMA Biologics Competitors $688.58 million $7.69 million -17.98

ADMA Biologics’ peers have higher revenue, but lower earnings than ADMA Biologics. ADMA Biologics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares ADMA Biologics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ADMA Biologics 35.14% 42.56% 26.96%
ADMA Biologics Competitors -12,224.75% -204.85% -31.52%

Insider & Institutional Ownership

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ADMA Biologics beats its peers on 7 of the 13 factors compared.

ADMA Biologics Company Profile

(Get Free Report)

ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida.

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.